Cationic liposomes as vaccine adjuvants

Expert Review of Vaccines

Volumn 6, Issue 5, 2007, Pages 785-796

  Christensen, Dennis ^a   Korsholm, Karen S ^a   Rosenkrands, Ida ^a   Lindenstrøm, Thomas ^a   Andersen, Peter ^a   Agger, Else Marie ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

1,2 dioleoyl 3 trimethylammonium propane; Adjuvant; Cationic liposome DC Chol; DDA; Delivery system; Immunomodulator; Vaccine

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYL SN GLYCERO 3 ETHYLPHOSPHOCHOLINE; 3BETA [N (N',N' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; ADJUVANT; AG85B ESAT 6 FUSION PROTEIN; ALUMINUM HYDROXIDE; AS 01; BCG VACCINE; CORD FACTOR; CPG OLIGODEOXYNUCLEOTIDE; DICETYL PHOSPHATE; DIMETHYLDIOCTADECYLAMMONIUM; DIPHTHERIA VACCINE; DNA VACCINE; HEPARIN; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; LIPOSOME; MURAMYL DIPEPTIDE; N [1 (2,3 DIOLEYLOXY)PROPYL] N,N,N TRIMETHYLAMMONIUM; N PALMITOYL DEXTRO ERYTHROSPINGOSYL 1 O CARBAMOYLSPERMINE; OCTADECENOYLLOXY(ETHYL 2 HEPTADECENYL 3 HYDROXYETHYL)IMIDAZOLINIUM; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; SQUALENE DERIVATIVE; TREHALOSE 6,6 DIBEHENATE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; CANCER; COMBINATION CHEMOTHERAPY; DRUG STRUCTURE; HUMAN; IMMUNE RESPONSE; LIPID BILAYER; MELANOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CATIONS; HUMANS; IMMUNOLOGIC FACTORS; LIPOSOMES; VACCINES;

EID: 35349027728     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.5.785     Document Type: Review

References (94)

1. Joseph A, Itskovitz-Cooper N, Samira S et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24(18), 3990-4006 (2006).
2. Latif N, Bachhawat BK. The effect of surface charges of liposomes in immunopotentiation. Biosci. Rep. 4(2), 99-107 (1984).
3. Nakanishi T, Kunisawa J, Hayashi A et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem. Biophys. Res. Commun. 240(3), 793-797 (1997).
4. Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19(23-24), 3301-3310 (2001).
5. Shi Y, Rock KL. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 32(1), 155-162 (2002).
6. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22(15-16), 1903-1913 (2004). • Investigating the relationship between surface charge and uptake by dendritic cells (DCs).
7. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 252(5480), 252 (1974).
8. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD Jr, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol. Membr. Biol. 23(5), 385-395 (2006). •• Investigating the ability of different liposomes to stimulate the expression of costimulatory molecules on DCs.
9. Mazumdar T, Anam K, Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22(9-10), 1162-1171 (2004).
10. Bomford R. The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation. Immunology 44(1), 187-192 (1981).
11. Kuramoto T, Nishikawa M, Thanaketpaisarn O, Okabe T, Yamashita F, Hashida M. Use of lipoplex-induced nuclear factor-κB activation to enhance transgene expression by lipoplex in mouse lung. J. Gene Med. 8(1), 53-62 (2006).
12. + T-cell response against protein antigens.
13. Mitchell LA, Joseph A, Kedar E, Barenholz Y, Galun E. Mucosal immunization against hepatitis A: antibody responses are enhanced by coadministration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine 24(25), 5300-5310 (2006).
14. Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit. Rev. Ther. Drug Carrier Syst. 21(4), 257-317 (2004).
15. Perrie Y, McNeil S, Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J. Drug Target. 11(8-10), 555-563 (2003).
16. Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J. Control. Release 119(1), 102-110 (2007).
17. Bei R, Guptill V, Masuelli L et al. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J. Immunother. 21(3), 159-169 (1998).
18. Walker C, Selby M, Erickson A, Cataldo D, Valensi JP, Van Nest GV. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc. Natl Acad. Sci. USA 89(17), 7915-7918 (1992).
19. Rejman J, Conese M, Hoekstra D. Gene transfer by means of lipo- and polyplexes: role of clathrin and caveolae-mediated endocytosis. J. Liposome Res. 16(3), 237-247 (2006).
20. Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 277(20), 18021-18028 (2002).
21. Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm. 2(1), 22-28 (2005).
22. Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 44(15), 3672-3681 (2007). •• Investigating the upregulation of cytokines and chemokines by 1,2-dioleoyl-3-trimethylammonium- propane (DOTAP) using microarray.
23. Hamm S, Heit A, Koffler M et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int. Immunol. 19(3), 297-304 (2007).
24. Loseke S, Grage-Griebenow E, Heine H et al. In vitro-generated viral double-stranded RNA in contrast to polyinosinic:polycytidylic acid induces interferon-? in human plasmacytoid dendritic cells. Scand. J. Immunol. 63(4), 264-274 (2006).
25. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 179(1), 280-285 (1991).
26. Brunel F, Darbouret A, Ronco J. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 17, 2192-2203 (1999).
27. Sanchez V, Gimenez S, Haensler J et al. Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol. Med. Microbiol. 30(2), 157-165 (2001).
28. Guy B, Pascal N, Francon A et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19(13-14), 1794-805 (2001).
29. Hattori Y, Kawakami S, Suzuki S, Yamashita F, Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem. Biophys. Res. Commun. 317(4), 992-999 (2004).
30. Cremel M, Hamzeh-Cognasse H, Genin C, Delezay O. Female genital tract immunization: evaluation of candidate immunoadjuvants on epithelial cell secretion of CCL20 and dendritic/Langerhans cell maturation. Vaccine 24(29-30), 5744-5754 (2006).
31. Davidsen J, Rosenkrands I, Christensen D et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta 1718(1-2), 22-31 (2005). •• Investigating the type of immune response generated by dimethyldioctadecylammonium/trehalose 6,6′-dibehenate (DDA/TDB) and characterizing the physical/chemical properties of the liposomes.
32. Feitosa E, Barreleiro PCA, Olofsson G. Phase transition in dioctadecyldimethylammonium bromide and chloride vesicles prepared by different Methods Chem. Phys. Lipids 105(2), 201-213 (2000).
33. Gall D. The adjuvant activity of aliphatic nitrogenous bases. Immunology 11(4), 369-386 (1966).
34. Dailey MO, Hunter RL. The role of lipid in the induction of hapten-specific delayed hypersensitivity and contact sensitivity. J. Immunol. 112(4), 1526-1534 (1974).
35. Snippe H, Belder M, Willers JM. Dimethyl diotadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice. Immunology 33(6), 931-936 (1977).
36. Katz D, Lehrer S, Galan O et al. Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines. Adv. Exp. Med. Biol. 397, 115-125 (1996).
37. Kraaijeveld CA, la Riviere G, Benaissa-Trouw BJ, Jansen J, Harmsen T, Snippe H. Effect of the adjuvant dimethyl dioctadecyl ammonium bromide on the humoral and cellular immune responses to encephalomyocarditis virus. Antiviral Res. 3(3), 137-149 (1983).
38. Klinguer-Hamour C, Libon C, Plotnicky-Gilquin H et al. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine 20(21-22), 2743-2751 (2002).
39. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65(2), 623-629 (1997).
40. Andersen P. The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology 191(4-5), 537-547 (1994).
41. Prager MD, Gordon WC. Enhanced response to chemoimmunotherapy and immunoprophylaxis with the use of tumor-associated antigens with a lipophilic agent. Cancer Res. 38(7), 2052-2057 (1978).
42. Stanfield JP, Gall D, Bracken PM. Singledose antenatal tetanus immunisation. Lancet 301(7797), 215-219 (1973).
43. Veronesi R, Correa A, Alterio D. Single dose immunization against tetanus. Promising results in human trials. Rev. Inst. Med. Trop. (Sao Paulo) 12(1), 46-54 (1970).
44. Hilgers LA, Snippe H. DDA as an immunological adjuvant. Res. Immunol. 143(5), 494-503 (1992).
45. Larsen ST, Hansen R, Hammer M, Tegner U, Poulsen OM, Nielsen GD. Adjuvant effect of quaternary ammonium compounds in a murine model. Toxicol. Lett. 151(2), 389-398 (2004).
46. Klinguer C, Beck A, De-Lys P et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when coadministered by the nasal route with vaccine antigens. Vaccine 19(30), 4236-4244 (2001).
47. Korsholm KS, Agger EM, Foged C et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121(2), 216-226 (2007). •• Demonstrating that DDA enhances antigen uptake and presentation by antigen-presenting cells.
48. Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs RJ. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J. Biol. Chem. 273(40), 26164-26170 (1998).
49. Rosenkrands I, Agger EM, Olsen AW et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect. Immun. 73(9), 5817-5826 (2005).
50. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517 (2007).
51. Qureshi N, Mascagni P, Ribi E, Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J. Biol. Chem. 260(9), 5271-5278 (1985).
52. Ribi E, Cantrell JL, Takayama K, Qureshi N, Peterson J, Ribi HO. Lipid A and immunotherapy. Rev. Infect. Dis. 6(4), 567-572 (1984).
53. Stewart VA, Walsh DS, McGrath SM et al. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine 24(42-43), 6493-6502 (2006).
54. Tsenova L, Harbacheuski R, Moreira AL et al. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect. Immun. 74(4), 2392-2401 (2006).
55. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68(2), 791-795 (2000).
56. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72(3), 1608-1617 (2004).
57. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B, ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72(10), 6148-6150 (2004).
58. Langermans JA, Doherty TM, Vervenne RA et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B, ESAT-6. Vaccine 23(21), 2740-2750 (2005).
59. Doherty TM, Olsen AW, van Pinxteren L, Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 70(6), 3111-3121 (2002).
60. Krieg AM, Yi AK, Hartmann G. Mechanisms and therapeutic applications of immune stimulatory CPG DNA. Pharmacol. Ther. 84(2), 113-120 (1999).
61. Dalpke A, Frank J, Peter M, Heeg K. Activation of Toll-like receptor 9 by DNA from different bacterial species. Infect. Immun. 74(2), 940-946 (2006).
62. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167(6), 3324-3328 (2001).
63. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6(11), 1867-1875 (1999).
64. Jiao X, Wang RY, Qiu Q, Alter HJ, Shih JW. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen, CpG with cationic liposomes. J. Gen. Virol. 85(6), 1545-1553 (2004).
65. + T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24(24), 5119-5132 (2006).
66. Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/β. Immunol. Cell. Biol. 82(6), 596-602 (2004).
67. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur. J. Immunol. 36(12), 3371-80 (2006).
68. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59(4), 1317-1325 (1974).
69. Woodard LF, Toone NM, McLaughlin CA. Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines. Infect. Immun. 30(2), 409-412 (1980).
70. Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278(11), 8869-8872 (2003).
71. Tada H, Aiba S, Shibata K, Ohteki T, Takada H. Synergistic effect of Nod1, Nod2 agonists with Toll-like receptor agonists on human dendritic cells to generate interleukin-12, T helper type 1 cells. Infect. Immun. 73(12), 7967-7976 (2005).
72. Dzata GK, Wyckoff JH 3rd, Confer AW. Immunopotentiation of cattle vaccinated with a soluble Brucella abortus antigen with low LPS content: an analysis of cellular and humoral immune responses. Vet. Microbiol. 29(1), 15-26 (1991).
73. Bekierkunst A, Yarkoni E, Flechner I, Morecki S, Vilkas E, Lederer E. Immune response to sheep red blood cells in mice pretreated with mycobacterial fractions. Infect. Immun. 4(3), 256-263 (1971).
74. Lima VM, Bonato VL, Lima KM et al. Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines, NO in tuberculosis. Infect. Immun. 69(9), 5305-5312 (2001).
75. Silva CL, Ekizlerian SM, Fazioli RA. Role of cord factor in the modulation of infection caused by mycobacteria. Am. J. Pathol. 118(2), 238-247 (1985).
76. Ryll R, Watanabe K, Fujiwara N et al. Mycobacterial cord factor, but not sulfolipid, causes depletion of NKT cells and upregulation of CD1d1 on murine macrophages. Microbes Infect. 3(8), 611-619 (2001).
77. Oswald IP, Dozois CM, Petit JF, Lemaire G. Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages. Infect. Immun. 65(4), 1364-1369 (1997).
78. Geisel RE, Sakamoto K, Russell DG, Rhoades ER. In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guerin is due principally to trehalose mycolates. J. Immunol. 174(8), 5007-5015 (2005).
79. Lima KM, Santos SA, Lima VM, Coelho-Castelo AA, Rodrigues JM Jr, Silva CL. Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis. Gene Ther. 10(8), 678-685 (2003).
80. Masihi KN, Lange W, Brehmer W, Ribi E. Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int. J. Immunopharmacol. 8(3), 339-345 (1986).
81. Coelho EA, Tavares CA, Lima Kde M, Silva CL, Rodrigues JM Jr, Fernandes AP. Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection. Parasitol. Res. 98(6), 568-575 (2006).
82. Vosika GJ, Schmidtke JR, Goldman A, Ribi E, Parker R, Gray GR. Intralesional immunotherapy of malignant melanoma with Mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (P3). Cancer 44(2), 495-503 (1979).
83. Hunter RL, Olsen M, Jagannath C, Actor JK. Trehalose 6,6′- dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice. Am. J. Pathol. 168(4), 1249-1261 (2006).
84. Fujita Y, Okamoto Y, Uenishi Y, Sunagawa M, Uchiyama T, Yano I. Molecular and supra-molecular structure related differences in toxicity and granulomatogenic activity of mycobacterial cord factor in mice. Microb. Pathog. 43(1), 10-21 (2007).
85. Nishizawa M, Yamamoto H, Imagawa H et al. Efficient syntheses of a series of trehalose dimycolate (TDM)/trehalose dicorynomycolate (TDCM) analogues and their interleukin-6 level enhancement activity in mice sera. J. Org. Chem. 72(5), 1627-1633 (2007).
86. Olds GR, Chedid L, Lederer E, Mahmoud AA. Induction of resistance to Schistosoma mansoni by natural cord factor and synthetic lower homologues. J. Infect. Dis. 141(4), 473-478 (1980).
87. Yarkoni E, Rapp HJ, Polonsky J, Lederer E. Immunotherapy with an intralesionally administered synthetic cord factor analogue. Int. J. Cancer 22(5), 564-569 (1978).
88. Pimm MV, Baldwin RW, Polonsky J, Lederer E. Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6,6′-dimycolate) and synthetic analogues. Int. J. Cancer 24(6), 780-785 (1979).
89. Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J. Pharm. Pharmacol. 58(6), 787-799 (2006).
90. Gavin AL, Hoebe K, Duong B et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314(5807), 1936-1938 (2006). • Analyzes antibody responses generated from typical adjuvants in mice lacking all Toll-like receptor (TLR) signaling and shows that TLRs are not prerequisite for their antibody responses.
91. Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein, CpG in Montanide induces integrated antibody/Th1 responses, CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA 104(21), 8947-8952 (2007). •• Shows that the effect of immunomodulators can be enhanced significantly when delivered in a suitable vehicle that serve to attract, interact and mediate the uptake of antigen as well as immunomodulators.
92. Christensen D, Foged C, Rosenkrands I, Nielsen HM, Andersen P, Agger EM. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochim. Biophys. Acta Biomembr. 1768(9), 2120-2129 (2007).
93. Mohammed AR, Bramwell VW, Coombes AG, Perrie Y. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods 40(1), 30-38 (2006).
94. Statens Serum Institut. WO2006002642 (2006).